AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial - Concepedia

Concepedia

Publication | Open Access

AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial

DOI Full Paper Access

93

Citations

44

References

2018

Year

Soraya Allas, Assumpta Caixàs, Christine Poitou, Muriel Coupaye, Denise Thuilleaux, F. Lorenzini, Gwénaëlle Diene, Antonino Crinò, F. Illouz, Graziano Grugni,

Abstract

AZP-531 may constitute a new treatment strategy to improve hyperphagia and metabolic issues in patients with PWS. These findings support further investigation in longer-term clinical trials.

References

	Year	Citations

Page 1